Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
September 30, 2019 08:45 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented updated...
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
September 09, 2019 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the...
Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients
August 27, 2019 08:00 ET
|
Adaptimmune Therapeutics plc; Noile-Immune Biotech, Inc.
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Noile-Immune Biotech,...
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
August 01, 2019 07:15 ET
|
Adaptimmune Therapeutics plc
- Started SPEARHEAD-1 clinical trial with ADP-A2M4 in synovial sarcoma and MRCLS patients – - Started low-dose radiation sub-study with ADP-A2M4 with the MD Anderson Cancer Center - - Started...
New Executive Team Announced at Adaptimmune
August 01, 2019 07:15 ET
|
Adaptimmune Therapeutics plc
- Adrian Rawcliffe to assume CEO role from September 1, 2019 - - John Lunger promoted to Chief Patient Supply Officer from August 1, 2019, as Adaptimmune gears up for commercial delivery of products...
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
July 25, 2019 08:00 ET
|
Adaptimmune Therapeutics plc
- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 25, 2019...
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
July 22, 2019 08:00 ET
|
Adaptimmune Therapeutics plc
- Compelling responses previously reported with ADP-A2M4 in sarcoma - - Use of low-dose radiation intended to enhance antitumor activity - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22,...
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
July 18, 2019 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 18, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc, Philadelphia, PA, and Oxfordshire, UK (Nasdaq:ADAP), a leader in T-cell therapy to treat...
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
June 27, 2019 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer...
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
May 15, 2019 08:00 ET
|
Adaptimmune Therapeutics plc; Alpine Immune Sciences, Inc.
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences,...